ArticleJournal for immunotherapy of cancer2026

PRTN3 drives immunosuppression in KRAS-mutant lung adenocarcinoma through proteolytic inactivation of CXCL9.

Yi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.